NSC 694621

MedChemExpress

HY-147288		
104857-29-6	5	
C ₁₃ H ₁₀ N ₂ O ₂ S		
258.3		
Histone Acetyltransferase		
Epigenetics		
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month
	104857-29-6 C ₁₃ H ₁₀ N ₂ O ₂ S 258.3 Histone Ace Epigenetics Powder	104857-29-6 C ₁₃ H ₁₀ N ₂ O ₂ S 258.3 Histone Acetyltransfe Epigenetics Powder -20°C 4°C In solvent -80°C

SOLVENT & SOLUBILITY

In Vitro

$\mathsf{DMSO}: 3.33 \mbox{ mg/mL}$ (12.89 mM; ultrasonic and warming and heat to $60^\circ\text{C})$

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.8715 mL	19.3573 mL	38.7147 mL
	5 mM	0.7743 mL	3.8715 mL	7.7429 mL
	10 mM	0.3871 mL	1.9357 mL	3.8715 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY					
Description	NSC 694621 is a potent PCAF inhibitor, with an IC ₅₀ of 5.71 μM (PCAF/H3 ₁₋₂₁). NSC 694621 exhibits good activity of inhibiting the proliferation of cancer cells ^[1] .				
IC ₅₀ & Target	IC50: 5.71 μM (PCAF/H3 ₁₋₂₁) ^[1] .				
In Vitro	NSC 694621 (25 μM; 72 h) exhibits antiproliferative effect to SK-N-SH and HCT116 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]				
	Cell Line:	SK-N-SH, HCT116 cells			
	Concentration:	25 μΜ			
	Incubation Time:	72 h			

Product Data Sheet

()/ 0 0

Showed antiproliferative effect to SK-N-SH and HCT116 cells with GI_{50} of 19.2 μM and growth inhibition of 29%, respectively.

REFERENCES

[1]. Furdas SD, et al. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg Med Chem. 2011 Jun 15;19(12):3678-89.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA